Retrospective Study
Copyright ©The Author(s) 2024.
World J Transplant. Sep 18, 2024; 14(3): 94914
Published online Sep 18, 2024. doi: 10.5500/wjt.v14.i3.94914
Table 5 Univariate and multivariate analysis for the endpoint of hepatocellular carcinoma recurrence
VariablesUnivariate analysis
Multivariate analysis
Hazard ratio (95%CI)
P value
Hazard ratio (95%CI)
P value
Sex1.88 (95%CI: 0.63-5.60)0.262.27 (95%CI: 0.64-8.02)0.22
Age at LT1.02 (95%CI: 0.98-1.07)0.841.01 (95%CI: 0.96-1.05)0.81
Aetiology of liver disease
        HBV2.09 (95%CI: 0.98-4.45)0.061.98 (95%CI: 0.92-4.27)0.081
        HCV1.68 (95%CI: 0.80-3.49)0.17
        NAFLD0.50 (95%CI: 0.14-1.78)0.28
        Statin use0.52 (95%CI: 0.22-1.26)0.400.52 (95%CI: 0.20-1.35)0.18
        Aspirin use0.32 (95%CI: 0.07-1.43)0.140.51 (95%CI: 0.14-1.93)0.32
        Metformin use0.90 (95%CI: 0.33-2.46)0.841.0 (95%CI: 0.37-2.72)1.00
        Statin, aspirin or metformin use10.61 (95%CI: 0.27-1.37)0.450.64 (95% 0.27-1.53)0.31
        MTORi use0.97 (95%CI: 0.49-1.93)0.940.68 (95%CI: 0.41-1.13)0.14
Pre LT co-morbidities
        Diabetes0.67 (95%CI: 0.30-1.51)0.33
        Stroke1.88 (95%CI: 0.26-13.50)0.53
        Hypertension0.67 (95%CI: 0.26-1.73)0.41
        Obesity0.96 (95%CI: 0.45-2.08)0.92
        Ischaemic heart diseaseN/AN/A
        Total cholesterol mmol/L0.59 (95%CI: 0.25-1.42)0.24
Other variables
        Microvascular invasion5.34 (95%CI: 2.54-11.21)< 0.014.04 (95%CI: 1.81-9.04)< 0.01
        AFP > 100 ng/mL pre-LT4.20 (95%CI: 1.86-9.51)< 0.013.14 (95%CI: 1.33-7.41)< 0.01
        Pre-LT regional treatments ≥ 32.27 (95%CI: 1.07-4.84)0.0331.46 (95%CI: 0.60-3.52)0.40
        Pre-LT size of largest lesion ≥ 3 cm3 (95%CI: 1.43-6.31)< 0.012.21 (0.96-5.06)0.062
        Beyond Milan4.31 (95%CI: 2.09-8.89)< 0.01
        Beyond up-to-74.59 (95%CI: 2.22-9.49)< 0.012.82 (95%CI: 1.35-5.89)< 0.01
        Complete response at LT0.36 (95%CI: 0.14-0.92))0.0340.66 (95%CI: 0.24-1.81)0.42